---
title: "Tellgen's subsidiary obtained 2 medical device registration certificates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/246034907.md"
description: "Tellgen's wholly-owned subsidiary Jiangxi Tellgen Life Science Technology Co., Ltd. recently obtained two medical device registration certificates issued by the Jiangxi Provincial Drug Administration. These products include the Fibrin (ogen) Degradation Products Detection Kit and the Plasmin-α2 Plasmin Inhibitor Complex Detection Kit. The acquisition of these registration certificates will enrich the company's chemiluminescence product line, meet the clinical needs for thrombosis testing, enhance the company's competitiveness in the in vitro diagnostic field, and promote market expansion"
datetime: "2025-06-25T08:20:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/246034907.md)
  - [en](https://longbridge.com/en/news/246034907.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/246034907.md)
generator: "portal-rs"
---

# Tellgen's subsidiary obtained 2 medical device registration certificates

According to the Zhitong Finance APP, Tellgen (300642.SZ) announced that its wholly-owned subsidiary, Jiangxi Tellgen Life Science Technology Co., Ltd., recently obtained two medical device registration certificates issued by the Jiangxi Provincial Drug Administration. The product names are: Fibrinogen (Original) Degradation Product Determination Kit (Chemiluminescent Immunoassay) and Plasminogen-α2 Plasmin Inhibitor Complex Determination Kit (Chemiluminescent Immunoassay).

The acquisition of the above medical device registration certificates enriches the company's and Jiangxi Tellgen's layout in the chemiluminescent product line, better meeting end-users' clinical diagnostic needs for thrombosis testing projects. This will further enhance the comprehensive competitiveness of the company and its subsidiaries in the field of in vitro diagnostics, which is beneficial for further improving market expansion capabilities and will have a positive impact on the company's future production and operations

### Related Stocks

- [300642.CN](https://longbridge.com/en/quote/300642.CN.md)

## Related News & Research

- [CARsgen FY26 H1 net loss narrows to RMB 70.84 million; revenue rises 21.49% to RMB 61.92 million](https://longbridge.com/en/news/296243257.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)
- [17:15 ETHost Defense® Launches New Functional Mushroom Supplement for Pets](https://longbridge.com/en/news/296402242.md)
- [07:55 ETSAPPHIRE LENSES & WINDOWS PROTECT SENSITIVE ELECTRO-OPTICAL SYSTEMS](https://longbridge.com/en/news/296224371.md)
- [04:20 ETSphingoTec to Engage with Clinical and Industry Partners at Major 2026 Conferences](https://longbridge.com/en/news/296322953.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**